By Industry News
Amniox Donates $10,000 to the American Diabetes Association (ADA)
Miami, FL – December 2, 2021 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company, announced today that it has gifted the American Diabetes Association (ADA) with a $10,000 donation to support scientific research and prediabetes education. Amniox has been a longtime proponent for the advancement of clinical research of this type. In November 2020, the organization launched their first of two multi center randomized controlled Phase 3 Clinical Trials studying human birth tissue-based products to treat complex Wagner Grade 3 and 4 diabetic foot ulcers. These studies are currently being conducted at 20 investigational sites across the United States.
This gift demonstrates Amniox’s long-standing commitment to the furtherance of scientific research. The organization is in solid alignment with the ADA’s longstanding commitment to support the next generation of diabetes researchers.
"We are proud to support the ADA and applaud the research and educational efforts of the ADA and Wound Healing Society,” said TissueTech President and Chief Executive Officer Amy Tseng. "For over a decade, Amniox has been recognized as a leader in complex wound management through our clinical research and medical contributions. Currently, we are conducting two clinical trials studying an investigational new drug to achieve complete wound closure of complex non-healing diabetic foot ulcers with high-risk factors of ulcer depth indicating exposed bone, tendon, muscle, and/or joint capsule, and clinical suspicion of osteomyelitis.”
Results from an earlier one-year, follow-up study published in the peer-reviewed journal Wound Repair and Regeneration indicates that TTAX01 is a promising adjunct therapy with a higher healing rate than Standard of Care (SOC) for the management of advanced diabetic foot ulcers complicated by osteomyelitis.1 The Amniox leadership team hopes to parley these research results to ultimately reduce health care costs when treating complex wounds. In one study published by the Alliance of Wound Care Stakeholders, researchers found that chronic non-healing wounds impact nearly 15% of Medicare beneficiaries (8.2 million) with an estimated annual cost is $28 billion.2
About TissueTech, Inc.
TissueTech, Inc. is an emerging biotechnology company in regenerative medicine using human birth tissue. TissueTech's amniotic membrane products are processed using its proprietary CRYOTEK® cryopreservation technology, designed to retain the tissue's structural and functional integrity. TissueTech has multiple Investigational New Drug clinical trials underway as the company pursues 351 biologics' approval for products to treat patients' clinical needs.
About Amniox Medical, Inc.
AMNIOX® Medical, Inc. is the first provider of a cryopreserved matrix comprised of human umbilical cord that can be stored in a refrigerator for up to two years and is ready to use without thawing, transplanting the benefits of regenerative healing for non-healing and chronic wounds.
- Marston, WA, Lantis, JC, Wu, SC, et al. One‐year safety, healing and amputation rates of Wagner 3‐4 diabetic foot ulcers treated with cryopreserved umbilical cord (TTAX01). Wound Rep Reg. 2020; 1– 6. https://doi.org/10.1111/wrr.12809 Marston, W. A., Lantis, J. C., Wu, S. C., Nouvong, A., Lee, T.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, HMP Global, its affiliates, or subsidiary companies.